NEW YORK (GenomeWeb News) – UBS today said it has downgraded Bruker BioSciences’ stock to “Neutral" from "Buy."
 
According to Reuters, the brokerage said Bruker’s Daltonics division “faces increasing competition from much larger mass spectrometry vendors, potentially limiting upside.”
 
UBS maintained its $7 price target on Bruker’s stock, Reuters said.
 
The stock was down 1.62 percent, or $.10, at 6.04 in mid-afternoon trading today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.